

Anatomical Workshop Wet Lab; Lower Limb

03.06.2025, 08:30h
Anatomical Institute
University, Bern

AbbVie
Medical
Institute

NEUROLITE
Advanced Medical Solutions

Promotional meeting
organised and funded by AbbVie.

abbvie

We are looking forward to welcoming you again to our popular workshops very soon.

The anatomical workshops are targeted at those of you who are looking for an advanced immersion and refresher of the functional anatomy and ultrasound-guided injection techniques of dystonic patients.

You will be introduced to the product and its methods of action, practice ultrasound-guided functional anatomy as well as review the anatomy in the wet lab and practice injecting on human specimens. Our experts will answer your questions and guide you through the pearls and pitfalls of Botulinumtoxin to solidify your confidence in your daily practice.

Time	Presentation
08:30 - 09:00	Doors open & registrations
09:00 - 09:30	Lower limb (functional anatomy and important landmarks)
09:30 - 10:00	Ultrasound-guided injection techniques – practical considerations
10:00 - 10:15	Coffee break
10:15 - 12:00	Ultrasound hands-on session
12:00 - 13:00	Lunch
13:00 - 16:00	Hands-on wet lab – injection techniques on the human specimen
16:00 - 17:00	Q&A, summary, closing remarks

Full day course – Theory and Wet Lab

Language: English/French

Date: 03.06.2025

Location: Anatomical Institute, University
Bühlstrasse 26, 3012 Bern

Time: 08:30 – 17:00


Trainers: *Prof. Dr. Laurent Tatu (F)*
Faculté de Médecine,
Laboratoire d'Anatomie, Besançon

Dr. Stefano Carda (CH)
CHUV – Service de Neuropsychologie
et Neuroréhabilitation, Lausanne

Credits: The workshop will be credited with 8 CME points according SNG

Sponsors: This workshop will be co-sponsored by Neurolite.

Reg. Fee: CHF 330.–



◀ Please register your interest for this Workshop



CH-BTX-240017 May 2024 | AbbVie AG | Alte Steinhäuserstr 14, 6330 Cham

abbvie | AMI

Succinct Statement BOTOX® (Toxinum botulinicum A) 50 and 100 Allergan-Units

I: Neurology: Symptomatic management of blepharospasm, hemifacial spasm and associated focal dystonias, for correction of strabismus in patients older than 12 years. Cervical dystonia (spasmodic torticollis) in adults, symptomatic treatment of focal spasticity of the upper and lower limbs in adults, adolescents and children from 2 years of age and older. Prophylaxis of headache in adult patients with chronic migraine. Skin: Primary hyperhidrosis of the axillae in adults. Bladder: Overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who have an inadequate response to, or are intolerant of, anticholinergic medication. Urinary incontinence due to neurogenic detrusor overactivity associated with a neurologic condition (such as spinal cord injury, multiple sclerosis) in adults. Neurogenic detrusor overactivity associated with a neurological disease (such as spina bifida, spinal cord lesion) in paediatric patients 5 years of age and older whose bladder is reliably emptied by regular disposable catheterization and who have an inadequate response to or are intolerant of anticholinergic medicinal products. **D:** Botulinum toxin units are not inter-changeable from one product to another product. Only be given by physicians with appropriate qualifications, expertise and equipment (e.g. EMG). Dosage depending on indication and individual treatment, optimum dose levels should be determined by titration. **CI:** Known hypersensitivity to the active substance or to any of the excipients. Infection at the proposed injection site(s). Injections into the detrusor: urinary tract infection, acute urinary retention without catheter. **W:** Do not exceed recommended dosages. Consideration should be given to the risk-benefit implications for the individual patient before treatment (history in neurological disorders, dysphagia and aspiration, epilepsy). Prior surgical procedures, injection into vulnerable anatomic structures, presence of inflammation at the proposed injection site, weakness/atrophy in the target muscle; swallowing, speech or respiratory disorders that require an immediate medical care, presence of contra measures in case of anaphylactic reactions; possible reduction of effectiveness by formation of neutralizing antibodies. Caution in patients with peripheral motor neuropathic diseases and defective neuromuscular transmission (e.g. myasthenia gravis or Lambert-Eaton Syndrome). Caution is warranted when injecting in proximity to the lung (particularly the apices). Immediate use of diluted solution in the syringe (e.g. urinary incontinence). **IA:** aminoglycoside antibiotics, spectinomycin or other medicinal products that interfere with neuromuscular transmission (e.g. muscle relaxants), other botulinum toxins. Do not mix with other medicinal products. Not recommended in women of childbearing potential not using contraception, during pregnancy and breastfeeding. **AE:** Very common: eyelid ptosis, eye movement disorder, dysphagia, muscular weakness, pain, urinary tract infection, dysuria, bacteriuria, urinary retention, residual urine volume, injection site pain. **P:** 2 x 1 vials with BOTOX® 50 Allergan Units. 1 and 2 x 1 vials with BOTOX® 100 Allergan Units. List A, with limitatio. **M:** AbbVie AG, Alte Steinhäuserstrasse 14, 6330 Cham, tel. (+41) 41 399 15 00. For detailed medicinal products characteristics see: www.swissmedinfo.ch (V4).

CH-BTX-240017 May 2024 | AbbVie AG | Alte Steinhäuserstr 14, 6330 Cham